HER2/neu cancer vaccine (University of Washington/Corixa/GSK)

N/A

Report date: 2026/03/26 20:00:17

Base Information

Drug NameHER2/neu cancer vaccine (University of Washington/Corixa/GSK)
Drug Alias Namemicrosphere encapsulated Her-2/neu peptide vaccineHer-2/neu vaccineHER2 antigen specific cancer immunotherapeuticHer-2/neu peptide vaccine E75 + GM-CSFHER-2/neu peptide vaccines + GM-CSF +[7] 
ClassificationVaccines > Application > Therapeutic vaccineVaccines > Development/production technology > Nucleic acid vaccine > DNA vaccine
Mechanisms of ActionReceptor protein-tyrosine kinase erbB-2 modulators
TargetsReceptor protein-tyrosine kinase erbB-2
Therapy Area/IndicationsLung NeoplasmsOvarian NeoplasmsBreast Neoplasms, Male +[4] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited States
CombinationsNo
Global Highest StatusPending (Phase 2 Clinical)
Highest Status in ChinaN/A
Originator CompaniesUniversity Of Washington
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesUniversity Of Washington
Active IndicationsN/A
Inactive IndicationsLung NeoplasmsOvarian NeoplasmsBreast Neoplasms, Male +[4] 

Other Information

ATC CodeN/A
Related LinksN/A